NASDAQ: EVGN
Evogene Ltd Stock

$0.35+0.01 (+2.94%)
Updated Nov 18, 2026
EVGN Price
$0.35
Fair Value Price
N/A
Market Cap
$4.74M
52 Week Low
$0.25
52 Week High
$1.26
P/E
-0.39x
P/B
-1.44x
P/S
5.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$957.00k
Earnings
-$9.07M
Gross Margin
-190.2%
Operating Margin
-446.6%
Profit Margin
-948.1%
Debt to Equity
-2.33
Operating Cash Flow
-$11M
Beta
0.92
Next Earnings
Nov 19, 2026
Ex-Dividend
N/A
Next Dividend
N/A

EVGN Overview

Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine EVGN's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
EVGN
Ranked
Unranked of 449

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important EVGN news, forecast changes, insider trades & much more!

EVGN News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EVGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
EVGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more EVGN due diligence checks available for Premium users.

Valuation

EVGN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.39x
Industry
17.98x
Market
41.36x

EVGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-1.44x
Industry
4.91x

EVGN's financial health

Profit margin

Revenue
$347.0k
Net Income
-$1.8M
Profit Margin
-509.5%
EVGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EVGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$13.4M
Liabilities
$7.7M
Debt to equity
-2.33
EVGN's short-term assets ($10.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVGN's short-term assets ($10.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EVGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.0M
Investing
$4.6M
Financing
-$1.8M
EVGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EVGN vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
EVGN–$4.74M+2.94%-0.39x-1.44x
PCSA–$4.76M-1.73%-0.03x-0.03x
JAGX–$4.71M-7.11%-0.00x0.23x
PULM–$4.89M-2.19%-1.12x3.64x
OPHID$4.91M-5.56%-0.36x1.67x

Evogene Stock FAQ

What is Evogene's quote symbol?

(NASDAQ: EVGN) Evogene trades on the NASDAQ under the ticker symbol EVGN. Evogene stock quotes can also be displayed as NASDAQ: EVGN.

If you're new to stock investing, here's how to buy Evogene stock.

What is the 52 week high and low for Evogene (NASDAQ: EVGN)?

(NASDAQ: EVGN) Evogene's 52-week high was $1.26, and its 52-week low was $0.25. It is currently -72.22% from its 52-week high and 40% from its 52-week low.

How much is Evogene stock worth today?

(NASDAQ: EVGN) Evogene currently has 13,535,843 outstanding shares. With Evogene stock trading at $0.35 per share, the total value of Evogene stock (market capitalization) is $4.74M.

Evogene stock was originally listed at a price of $9.62 in Oct 15, 2010. If you had invested in Evogene stock at $9.62, your return over the last 16 years would have been -96.36%, for an annualized return of -18.71% (not including any dividends or dividend reinvestments).

How much is Evogene's stock price per share?

(NASDAQ: EVGN) Evogene stock price per share is $0.35 today (as of Nov 18, 2026).

What is Evogene's Market Cap?

(NASDAQ: EVGN) Evogene's market cap is $4.74M, as of Nov 19, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Evogene's market cap is calculated by multiplying EVGN's current stock price of $0.35 by EVGN's total outstanding shares of 13,535,843.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.